p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas
- PMID: 7914423
- PMCID: PMC2033485
- DOI: 10.1038/bjc.1994.296
p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas
Abstract
Bronchial epithelial dysplasia is thought to be a premalignant stage in the evolution of lung cancers. Using the CM-1 polyclonal antibody, we have examined the expression of the p53 protein in a larger series of bronchial dysplasias (n = 60) than hitherto investigated. The p53 protein was detected in 14% of mild, 25% of moderate and 59% of severe dysplasias; increased p53 expression correlated with the severity of dysplasia. p53-positive dysplasias had greater PCNA indices than p53-negative dysplasias. p53 expression in dysplastic tissues was compared with that in two groups of histologically normal epithelium: 14 bronchial biopsies from non-cancer patients of which all but one were negative and 32 bronchial margins from resected carcinomas, of which 17 showed infrequent solitary cells with p53-positive nuclei in predominantly basal locations scattered throughout the epithelium. These results for resection margins were confirmed by use of a second antibody, DO-1. Sixty-nine per cent of the corresponding carcinomas were p53 positive, but in 15 cases the p53 reactivity differed from resection margins. No correlation between p53 expression and any of the clinicopathological characteristics of these tumours was found. This study supports the observation that abnormal p53 expression may be an early but not obligatory event in malignant transformation in lung.
Similar articles
-
Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas.Br J Cancer. 1995 Jul;72(1):164-9. doi: 10.1038/bjc.1995.295. Br J Cancer. 1995. PMID: 7599047 Free PMC article.
-
High incidence of chromosomal abnormalities at 1p36 and 9p21 in early-stage central type squamous cell carcinoma and squamous dysplasia of bronchus detected by autofluorescence bronchoscopy.Oncol Rep. 2009 Jul;22(1):81-7. doi: 10.3892/or_00000409. Oncol Rep. 2009. PMID: 19513508
-
P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study.Eur Respir J. 2000 Mar;15(3):547-52. doi: 10.1034/j.1399-3003.2000.15.20.x. Eur Respir J. 2000. PMID: 10759451
-
Apoptotic activity is increased in parallel with the metaplasia-dysplasia-carcinoma sequence of the bronchial epithelium.Br J Cancer. 1999 Feb;79(5-6):996-1002. doi: 10.1038/sj.bjc.6690159. Br J Cancer. 1999. PMID: 10070903 Free PMC article.
-
[Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].Verh Dtsch Ges Pathol. 1993;77:241-6. Verh Dtsch Ges Pathol. 1993. PMID: 7511289 Review. German.
Cited by
-
p53 gene product expression in resected non-small cell carcinoma of the lung, with studies of concurrent cytological preparations and microwave antigen retrieval.J Clin Pathol. 1997 Apr;50(4):320-3. doi: 10.1136/jcp.50.4.320. J Clin Pathol. 1997. PMID: 9215149 Free PMC article.
-
New prognostic factors in resectable non-small cell lung cancer.Thorax. 1996 Jun;51(6):638-46. doi: 10.1136/thx.51.6.638. Thorax. 1996. PMID: 8693450 Free PMC article. Review. No abstract available.
-
Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis.Pathol Oncol Res. 2001;7(1):33-8. doi: 10.1007/BF03032602. Pathol Oncol Res. 2001. PMID: 11349218
-
Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.Pathol Oncol Res. 1999;5(4):285-90. doi: 10.1053/paor.1999.0185. Pathol Oncol Res. 1999. PMID: 10607923
-
Clinical implication of p53 mutation in lung cancer.Mol Biotechnol. 2003 Jun;24(2):141-56. doi: 10.1385/MB:24:2:141. Mol Biotechnol. 2003. PMID: 12746555 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous